
OptimizeRx Corp (OPRX) Stock Forecast & Price Target
OptimizeRx Corp (OPRX) Analyst Ratings
Bulls say
OptimizeRx is well-positioned for growth with its proprietary communication network for healthcare professionals and a strong potential for revenue growth given its access to the $19 billion pharmaceutical digital advertising market. The company has a solid track record of maintaining profitability through cost actions and strong margins, and is continuously expanding its customer base and partnerships. However, risks include reliance on a concentrated group of customers and partners, as well as potential competition in the market.
Bears say
OptimizeRx is currently facing execution issues with a large client and the effects of continued headwinds related to Most Favored Nation (MFN) pricing and economic uncertainty, leading to a lowered revenue guidance for 2026. Despite growth drivers such as AI-enabled DAAP and mid-tier pharma, the company's revenue visibility remains lower than the previous year and the rest of the year may see a decline in net revenue retention due to large pharma volatility. However, the company's programmatic EHR/DSP connection has the potential to add future growth opportunities in the digital healthcare market.
This aggregate rating is based on analysts' research of OptimizeRx Corp and is not a guaranteed prediction by Public.com or investment advice.
OptimizeRx Corp (OPRX) Analyst Forecast & Price Prediction
Start investing in OptimizeRx Corp (OPRX)
Order type
Buy in
Order amount
Est. shares
0 shares